Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Biopharmaceutical company licenses phase II clinical anticancer compound
June 2nd, 2005
Miikana Therapeutics, Inc., announced an exclusive worldwide license to Roche's compound, MKC-1. This novel, orally active, anticancer agent has demonstrated activity against breast cancer and non-small cell lung cancer in phase II clinical trials. Under the terms of the agreement, Miikana receives an exclusive worldwide license to develop, manufacture, and commercialize MKC-1. In addition to an equity stake in Miikana, Roche will receive undisclosed upfront, milestone and royalty payments. "The acquisition of MKC-1 accelerates the evolution of Miikana into a clinical-stage oncology company in less than 2 years, and is in line with our business...
Source: Women's Health Weekly (2005-06-02)
|
